

Marin H Kollef

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7502077/publications.pdf>

Version: 2024-02-01

380
papers

42,099
citations

2197

102
h-index

2750

198
g-index

385
all docs

385
docs citations

385
times ranked

21859
citing authors

#	ARTICLE	IF	CITATIONS
1	Race Does Not Impact Sepsis Outcomes When Considering Socioeconomic Factors in Multilevel Modeling. <i>Critical Care Medicine</i> , 2022, 50, 410-417.	0.4	5
2	Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e74-e87.	4.6	10
3	Prospective Nasal Screening for Methicillin-Resistant <i>Staphylococcus aureus</i> in Critically Ill Patients With Suspected Pneumonia. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab578.	0.4	3
4	Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1166-1177.	1.3	7
5	Classical and Molecular Techniques to Diagnose HAP/VAP. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 219-228.	0.8	3
6	Life-Threatening Infections: Pulmonary and Systemic Infections. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 001-002.	0.8	1
7	Impact of Stress Ulcer Prophylaxis Discontinuation Guidance in Mechanically Ventilated, Critically Ill Patients: A Pre-Post Cohort Study. <i>Hospital Pharmacy</i> , 2022, 57, 510-517.	0.4	3
8	How to use new antibiotics in the therapy of ventilator-associated pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 140-148.	1.3	1
9	Mechanical Ventilation Practices and Low Tidal Volume Ventilation in Air Medical Transport Patients: The AIR-VENT Study. <i>Respiratory Care</i> , 2022, 67, 647-656.	0.8	1
10	Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia. <i>Medicine (United States)</i> , 2022, 101, e29159.	0.4	0
11	$\hat{\mu}$ -Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value. , 2022, 4, e0726.		14
12	Next Steps in Pneumonia Severity Scores. <i>Clinical Infectious Diseases</i> , 2021, 72, 950-952.	2.9	2
13	Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 213-225.	4.6	255
14	Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	1
15	Racial Disparities in Readmissions Following Initial Hospitalization for Sepsis. <i>Critical Care Medicine</i> , 2021, 49, e258-e268.	0.4	9
16	Nosocomial Infection. <i>Critical Care Medicine</i> , 2021, 49, 169-187.	0.4	82
17	Pneumococcal community-acquired pneumonia in the intensive care unit: Azithromycin remains protective despite macrolide resistance. <i>Respiratory Medicine</i> , 2021, 177, 106307.	1.3	6
18	Comparison of Sepsis Definitions as Automated Criteria. <i>Critical Care Medicine</i> , 2021, 49, e433-e443.	0.4	15

#	ARTICLE	IF	CITATIONS
19	Characteristics of U.S. Acute Care Hospitals That Have Implemented Telemedicine Critical Care. , 2021, 3, e0468.		14
20	A Pragmatic Machine Learning Model To Predict Carbapenem Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0006321.	1.4	11
21	New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam. Antimicrobial Agents and Chemotherapy, 2021, 65, e0231820.	1.4	17
22	Initial antimicrobial management of sepsis. Critical Care, 2021, 25, 307.	2.5	58
23	Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial. Critical Care, 2021, 25, 290.	2.5	21
24	Monoclonal antibodies as antibacterial therapies: thinking outside of the box. Lancet Infectious Diseases, The, 2021, 21, 1201-1202.	4.6	7
25	Spot the difference: comparing results of analyses from real patient data and synthetic derivatives. JAMIA Open, 2021, 3, 557-566.	1.0	33
26	Timing of antibiotic therapy in the ICU. Critical Care, 2021, 25, 360.	2.5	54
27	Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial. Critical Care, 2021, 25, 354.	2.5	14
28	Short- Versus Standard-Course Nonmacrolide Antibiotic Treatment in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Retrospective, Observational Cohort Study. Clinical Therapeutics, 2021, , .	1.1	1
29	The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. Drugs, 2021, 81, 2117-2131.	4.9	161
30	Assessment of Antibiotic De-escalation by Spectrum Score in Patients With Nosocomial Pneumonia: A Single-Center, Retrospective Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab508.	0.4	9
31	Vancomycin/Piperacillin-tazobactam Nephrotoxicity in the Critically Ill. Clinical Infectious Diseases, 2020, 70, 1520-1521.	2.9	3
32	Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia – Authors' reply. Lancet Infectious Diseases, The, 2020, 20, 20-21.	4.6	0
33	Impact of Baseline Characteristics on Future Episodes of Bloodstream Infections: Multistate Model in Septic Patients With Bloodstream Infections. Clinical Infectious Diseases, 2020, 71, 3103-3109.	2.9	4
34	Microbiologic Failure Despite Clinical Cure in Pneumonia: Cum Hoc and Post Hoc Ergo Propter Hoc. Clinical Infectious Diseases, 2020, 71, 3042-3043.	2.9	0
35	Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Medicine, 2020. 46. 245-265.	3.9	97
36	Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial. Infectious Diseases and Therapy, 2020, 9, 953-966.	1.8	3

#	ARTICLE	IF	CITATIONS
37	A PRAGMATIC MACHINE LEARNING MODEL TO PREDICT CARBAPENEM RESISTANCE. <i>Chest</i> , 2020, 158, A706.	0.4	1
38	Culture-negative sepsis. <i>Current Opinion in Critical Care</i> , 2020, 26, 473-477.	1.6	24
39	Bacterial and fungal superinfections in critically ill patients with COVID-19. <i>Intensive Care Medicine</i> , 2020, 46, 2071-2074.	3.9	79
40	Limitations of Registration Trials for Nosocomial Pneumonia. <i>Clinical Infectious Diseases</i> , 2020, 73, e4549-e4551.	2.9	2
41	Pulmonary infections complicating ARDS. <i>Intensive Care Medicine</i> , 2020, 46, 2168-2183.	3.9	69
42	Characteristics and outcomes among a hospitalized patient cohort with <i>Streptococcus pneumoniae</i> infection. <i>Medicine (United States)</i> , 2020, 99, e20145.	0.4	4
43	Bloodstream Infections and Delayed Antibiotic Coverage Are Associated With Negative Hospital Outcomes in Hematopoietic Stem Cell Transplant Recipients. <i>Chest</i> , 2020, 158, 1385-1396.	0.4	5
44	Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1478.	3.8	419
45	PROPHETIC. <i>Chest</i> , 2020, 158, 2370-2380.	0.4	19
46	Evaluation of a ceiling effect on the association of new resistance development to antipseudomonal beta-lactam exposure in the critically ill. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 484-485.	1.0	7
47	1477. Impact Of Resistance Thresholds On Mortality In Hospital-Acquired And Ventilator-Associated Pneumonia. <i>Open Forum Infectious Diseases</i> , 2020, 7, S739-S740.	0.4	0
48	Pathogen-Negative Sepsis—An Opportunity for Antimicrobial Stewardship. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz397.	0.4	10
49	Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1299-1311.	4.6	218
50	Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia. <i>Clinical Therapeutics</i> , 2019, 41, 2540-2548.	1.1	7
51	Redefining the Threshold for Broad-Spectrum Antibiotics. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1367-1369.	1.5	0
52	Novel Approaches to Hasten Detection of Pathogens and Antimicrobial Resistance in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 454-464.	0.8	12
53	Challenges in severe community-acquired pneumonia: a point-of-view review. <i>Intensive Care Medicine</i> , 2019, 45, 159-171.	3.9	100
54	Rebuttal From Drs Aguilar and Kollef. <i>Chest</i> , 2019, 155, 668-669.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Reduction in antimicrobial use among medical intensive care unit patients during a cluster randomized crossover trial of palliative care consultation. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 491-492.	1.0	3
56	POINT: Does Persistent or Worsening ARDS Refractory to Optimized Ventilation and Proning Deserve a Trial of Prostacyclin? Yes. <i>Chest</i> , 2019, 155, 662-665.	0.4	5
57	Clinical Effect of Expedited Pathogen Identification and Susceptibility Testing for Gram-Negative Bacteremia and Candidemia by Use of the Accelerate Pheno™ System. <i>Journal of Applied Laboratory Medicine</i> , 2019, 3, 569-579.	0.6	17
58	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. <i>Clinical Infectious Diseases</i> , 2019, 69, 1912-1918.	2.9	24
59	Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	55
60	Moving the Practice of Respiratory Therapy Forward. <i>Respiratory Care</i> , 2019, 64, 1014-1016.	0.8	1
61	Early Palliative Care Consultation in the Medical ICU: A Cluster Randomized Crossover Trial. <i>Critical Care Medicine</i> , 2019, 47, 1707-1715.	0.4	90
62	Cluster analysis to define distinct clinical phenotypes among septic patients with bloodstream infections. <i>Medicine (United States)</i> , 2019, 98, e15276.	0.4	18
63	Re-estimating annual deaths due to multidrug-resistant organism infections. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 112-113.	1.0	91
64	Outcomes Associated With De-escalating Therapy for Methicillin-Resistant <i>Staphylococcus aureus</i> in Culture-Negative Nosocomial Pneumonia. <i>Chest</i> , 2019, 155, 53-59.	0.4	36
65	Postoperative Pneumonia Prevention in Pulmonary Resections: A Feasibility Pilot Study. <i>Annals of Thoracic Surgery</i> , 2019, 107, 262-270.	0.7	5
66	Rationalizing antimicrobial therapy in the ICU: a narrative review. <i>Intensive Care Medicine</i> , 2019, 45, 172-189.	3.9	155
67	New antibiotics for community-acquired pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 169-175.	1.3	32
68	Antibiotic Thresholds for Sepsis and Septic Shock. <i>Clinical Infectious Diseases</i> , 2019, 69, 938-940.	2.9	4
69	A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	15
70	Duration of Exposure to Antipseudomonal β -Lactam Antibiotics in the Critically Ill and Development of New Resistance. <i>Pharmacotherapy</i> , 2019, 39, 261-270.	1.2	116
71	2226. Impact of Prior and Concomitant Antibacterial Therapy on Outcomes in the ASPECT-NP Randomized, Controlled Trial of Ceftolozane/Tazobactam (C/T) vs. Meropenem (MEM) in Patients with Ventilated Nosocomial Pneumonia (NP). <i>Open Forum Infectious Diseases</i> , 2019, 6, S760-S760.	0.4	0
72	Reply to MacFadden et al. <i>Clinical Infectious Diseases</i> , 2018, 66, 479-480.	2.9	0

#	ARTICLE	IF	CITATIONS
73	Sepsis-Associated Coagulopathy Severity Predicts Hospital Mortality*. Critical Care Medicine, 2018, 46, 736-742.	0.4	90
74	Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	20
75	Treatment of severe skin and soft tissue infections: a review. Current Opinion in Infectious Diseases, 2018, 31, 113-119.	1.3	36
76	Readmissions With Multidrug-Resistant Infection in Patients With Prior Multidrug Resistant Infection. Infection Control and Hospital Epidemiology, 2018, 39, 12-19.	1.0	16
77	Thirty-day hospital readmissions among mechanically ventilated emergency department patients. Emergency Medicine Journal, 2018, 35, 252-256.	0.4	4
78	The Burden of Viruses in Pneumonia Associated With Acute Respiratory Failure. Chest, 2018, 154, 84-90.	0.4	41
79	Acinetobacter Pneumonia: Improving Outcomes With Early Identification and Appropriate Therapy. Clinical Infectious Diseases, 2018, 67, 1455-1462.	2.9	27
80	Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: Shifting burden of disease?. American Journal of Infection Control, 2018, 46, 1092-1096.	1.1	11
81	Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections. Open Forum Infectious Diseases, 2018, 5, ofy026.	0.4	68
82	Frequent Versus Infrequent Monitoring of Endotracheal Tube Cuff Pressures. Respiratory Care, 2018, 63, 495-501.	0.8	33
83	Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	9
84	qSOFA score: Predictive validity in Enterobacteriaceae bloodstream infections. Journal of Critical Care, 2018, 43, 143-147.	1.0	10
85	Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infectious Diseases, The, 2018, 18, 285-295.	4.6	300
86	Monocyte Function and Clinical Outcomes in Febrile and Afebrile Patients With Severe Sepsis. Shock, 2018, 50, 381-387.	1.0	27
87	Risk Factors and Outcomes for Ineffective Empiric Treatment of Sepsis Caused by Gram-Negative Pathogens: Stratification by Onset of Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	16
88	1008. Cluster Analysis to Define Distinct Clinical Phenotypes Among Septic Patients With Bloodstream Infections. Open Forum Infectious Diseases, 2018, 5, S300-S300.	0.4	0
89	2521 Use of forced air warming devices to induce fever-range hyperthermia in critically ill septic patients. Journal of Clinical and Translational Science, 2018, 2, 50-50.	0.3	0
90	Catheter removal and outcomes of multidrug-resistant central-line-associated bloodstream infection. Medicine (United States), 2018, 97, e12782.	0.4	29

#	ARTICLE	IF	CITATIONS
91	1894. Antimicrobial Stewardship in the Intensive Care Unit: Survey of Critical Care and Infectious Diseases Physicians. <i>Open Forum Infectious Diseases</i> , 2018, 5, S543-S543.	0.4	0
92	872. PROPHETIC: Predicting Pneumonia in Hospitalized Patients in the ICU—A Model and Scoring System. <i>Open Forum Infectious Diseases</i> , 2018, 5, S25-S25.	0.4	0
93	Is Zero Ventilator-Associated Pneumonia Achievable?. <i>Clinics in Chest Medicine</i> , 2018, 39, 809-822.	0.8	15
94	The most recent concepts for the management of bacterial and fungal infections in ICU. <i>Intensive Care Medicine</i> , 2018, 44, 2000-2003.	3.9	4
95	Prevention of hospital-acquired pneumonia. <i>Current Opinion in Critical Care</i> , 2018, 24, 370-378.	1.6	33
96	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. <i>ERJ Open Research</i> , 2018, 4, 00028-2018.	1.1	41
97	Using wearable technology to predict health outcomes: a literature review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 1221-1227.	2.2	60
98	Differences in mortality between infections due to extended-spectrum-beta-lactamase-producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> . <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 1138-1139.	1.0	3
99	The carbon footprint of treating patients with septic shock in the intensive care unit. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2018, 20, 304-312.	0.0	11
100	“Does this patient have sepsis?”—Does this patient at risk for infection with multidrug resistant bacteria? <i>Intensive Care Medicine</i> , 2017, 43, 436-439.	3.9	8
101	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. <i>Intensive Care Medicine</i> , 2017, 43, 1187-1197.	3.9	103
102	Association between augmented renal clearance and clinical outcomes in patients receiving β -lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 624-630.	1.1	80
103	Viruses are prevalent in non-ventilated hospital-acquired pneumonia. <i>Respiratory Medicine</i> , 2017, 122, 76-80.	1.3	53
104	COUNTERPOINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? No. <i>Chest</i> , 2017, 151, 740-743.	0.4	9
105	Rebuttal From Dr Kollef. <i>Chest</i> , 2017, 151, 744-745.	0.4	1
106	Ventilator-Associated Pneumonia: The Role of Emerging Diagnostic Technologies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 253-263.	0.8	26
107	Prevention of <i>Staphylococcus aureus</i> Ventilator-Associated Pneumonia: Conventional Antibiotics Won't Cut It. <i>Clinical Infectious Diseases</i> , 2017, 64, 1089-1091.	2.9	5
108	A Respiratory Therapist Disease Management Program for Subjects Hospitalized With COPD. <i>Respiratory Care</i> , 2017, 62, 1-9.	0.8	22

#	ARTICLE	IF	CITATIONS
109	To which extent can we decrease antibiotic duration in critically ill patients?. Expert Review of Clinical Pharmacology, 2017, 10, 1215-1223.	1.3	7
110	Principles of antimicrobial stewardship for bacterial and fungal infections in ICU. Intensive Care Medicine, 2017, 43, 1894-1897.	3.9	2
111	A Prospective One-Year Microbiologic Survey of Combined Pneumonia and Respiratory Failure. Surgical Infections, 2017, 18, 827-833.	0.7	9
112	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. European Respiratory Journal, 2017, 50, 1700582.	3.1	792
113	Controversies and advances in the management of ventilator associated pneumonia. Expert Review of Respiratory Medicine, 2017, 11, 875-884.	1.0	13
114	The author replies. Critical Care Medicine, 2017, 45, e630-e631.	0.4	0
115	ICD-9-CM Coding for Multidrug Resistant Infection Correlates Poorly With Microbiologically Confirmed Multidrug Resistant Infection. Infection Control and Hospital Epidemiology, 2017, 38, 1381-1383.	1.0	6
116	CAP, HCAP, HAP,ÂVAP. Chest, 2017, 152, 909-910.	0.4	7
117	Predicting Resistance to Piperacillin-Tazobactam, Cefepime and Meropenem in Septic Patients With Bloodstream Infection Due to Gram-Negative Bacteria. Clinical Infectious Diseases, 2017, 65, 1607-1614.	2.9	37
118	A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia. Chest, 2017, 151, 1239-1246.	0.4	136
119	Augmented renal clearance is not a risk factor for mortality in Enterobacteriaceae bloodstream infections treated with appropriate empiric antimicrobials. PLoS ONE, 2017, 12, e0180247.	1.1	9
120	Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study. Critical Care, 2017, 21, 180.	2.5	23
121	Evaluating the Value of the Respiratory Therapist: Where Is the Evidence? Focus on the Barnes-Jewish Hospital Experience. Respiratory Care, 2017, 62, 1602-1610.	0.8	16
122	The authors reply. Critical Care Medicine, 2016, 44, e231-e232.	0.4	0
123	Real-time automated clinical deterioration alerts predict thirty-day hospital readmission. Journal of Hospital Medicine, 2016, 11, 768-772.	0.7	3
124	The authors reply. Critical Care Medicine, 2016, 44, e50-e51.	0.4	0
125	The Impact of Nighttime Intensivists on Medical Intensive Care Unit Infection-Related Indicators. Infection Control and Hospital Epidemiology, 2016, 37, 352-354.	1.0	5
126	In 2035, will all bacteria be multiresistant? Yes. Intensive Care Medicine, 2016, 42, 2014-2016.	3.9	8

#	ARTICLE	IF	CITATIONS
127	A Case-Control Study Assessing the Impact of Nonventilated Hospital-Acquired Pneumonia on Patient Outcomes. <i>Chest</i> , 2016, 150, 1008-1014.	0.4	99
128	Diagnosis and management of skin and soft tissue infections in the intensive care unit: a review. <i>Intensive Care Medicine</i> , 2016, 42, 1899-1911.	3.9	56
129	Secular trends in <i>Acinetobacter baumannii</i> resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study. <i>Journal of Hospital Medicine</i> , 2016, 11, 21-26.	0.7	82
130	Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate <i>Staphylococcus aureus</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5546-5553.	1.4	16
131	A targeted educational intervention to reduce ventilator-associated complications. <i>American Journal of Infection Control</i> , 2016, 44, 1406-1407.	1.1	3
132	Use of a Shared Canister Protocol for the Delivery of Metered-Dose Inhalers in Mechanically Ventilated Subjects. <i>Respiratory Care</i> , 2016, 61, 1285-1292.	0.8	3
133	Editorial Commentary: Antimicrobial De-escalation: What's in a Name?. <i>Clinical Infectious Diseases</i> , 2016, 62, 1018-1020.	2.9	8
134	Randomized Controlled Trial to Determine the Impact of Probiotic Administration on Colonization With Multidrug-Resistant Organisms in Critically Ill Patients. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1451-1454.	1.0	24
135	<i>Pseudomonas aeruginosa</i> Nosocomial Pneumonia: Impact of Pneumonia Classification. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1190-1197.	1.0	34
136	Targeted Fluid Minimization Following Initial Resuscitation in Septic Shock. <i>Chest</i> , 2015, 148, 1462-1469.	0.4	64
137	Pneumonia Pathogen Characterization Is an Independent Determinant of Hospital Readmission. <i>Chest</i> , 2015, 148, 103-111.	0.4	27
138	An international multicenter retrospective study of <i>Pseudomonas aeruginosa</i> nosocomial pneumonia: impact of multidrug resistance. <i>Critical Care</i> , 2015, 19, 219.	2.5	209
139	Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship. <i>Critical Care</i> , 2015, 19, 404.	2.5	32
140	Outcomes associated with bacteremia in the setting of methicillin-resistant <i>Staphylococcus aureus</i> pneumonia: a retrospective cohort study. <i>Critical Care</i> , 2015, 19, 312.	2.5	15
141	Impact of Sepsis Classification and Multidrug-Resistance Status on Outcome Among Patients Treated With Appropriate Therapy*. <i>Critical Care Medicine</i> , 2015, 43, 1580-1586.	0.4	59
142	Risk factors for 30-day readmission among patients with culture-positive severe sepsis and septic shock: A retrospective cohort study. <i>Journal of Hospital Medicine</i> , 2015, 10, 678-685.	0.7	14
143	Update on ventilator-associated pneumonia. <i>Current Opinion in Critical Care</i> , 2015, 21, 430-438.	1.6	26
144	Ventilator-Associated Pneumonia. <i>Chest</i> , 2015, 147, 1448-1450.	0.4	9

#	ARTICLE	IF	CITATIONS
145	Clinical effectiveness of a sedation protocol minimizing benzodiazepine infusions and favoring early dexmedetomidine: a before-after study. <i>Critical Care</i> , 2015, 19, 136.	2.5	17
146	A Prospective Evaluation of Ventilator-Associated Conditions and Infection-Related Ventilator-Associated Conditions. <i>Chest</i> , 2015, 147, 68-81.	0.4	106
147	Ten old antibiotics that will never disappear. <i>Intensive Care Medicine</i> , 2015, 41, 1950-1953.	3.9	1
148	Surveillance versus clinical adjudication: Differences persist with new ventilator-associated event definition. <i>American Journal of Infection Control</i> , 2015, 43, 589-591.	1.1	15
149	The Use of Inhaled Prostaglandins in Patients With ARDS. <i>Chest</i> , 2015, 147, 1510-1522.	0.4	106
150	Ventilator-associated Pneumonia Prevention. Is It Worth It?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 5-7.	2.5	10
151	Management of Infections with Drug-Resistant Organisms in Critical Care. <i>Clinics in Chest Medicine</i> , 2015, 36, 531-541.	0.8	6
152	Understanding toxic shock syndrome. <i>Intensive Care Medicine</i> , 2015, 41, 1707-1710.	3.9	31
153	Development and validation of a clinical prediction rule for candidemia in hospitalized patients with severe sepsis and septic shock. <i>Journal of Critical Care</i> , 2015, 30, 715-720.	1.0	26
154	The number of discharge medications predicts thirty-day hospital readmission: a cohort study. <i>BMC Health Services Research</i> , 2015, 15, 282.	0.9	73
155	If antibiotics did not exist. <i>Intensive Care Medicine</i> , 2015, 41, 525-527.	3.9	1
156	Mortality Prediction in ICUs Using A Novel Time-Slicing Cox Regression Method. <i>AMIA ... Annual Symposium proceedings</i> , 2015, 2015, 1289-95.	0.2	5
157	1233A Comparison of National Healthcare Safety Network (NHSN) Ventilator Associated Pneumonia (VAP) and Ventilator Associated Event (VAE) Definitions. <i>Open Forum Infectious Diseases</i> , 2014, 1, S45-S45.	0.4	2
158	1658C. <i>difficile</i> Recurrence is a Strong Predictor of 30-day Rehospitalization Among ICU Patients. <i>Open Forum Infectious Diseases</i> , 2014, 1, S443-S443.	0.4	0
159	881New Ventilator Associated Event (VAE) Definition: Persistence of Subjective Variability. <i>Open Forum Infectious Diseases</i> , 2014, 1, S253-S253.	0.4	0
160	A randomized trial of real-time automated clinical deterioration alerts sent to a rapid response team. <i>Journal of Hospital Medicine</i> , 2014, 9, 424-429.	0.7	78
161	Treatment of gram - positive infections in critically ill patients. <i>BMC Infectious Diseases</i> , 2014, 14, 92.	1.3	32
162	Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3581-3581.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Predictors of Outcome in 216 Subjects With ARDS Treated With Inhaled Epoprostenol. <i>Respiratory Care</i> , 2014, 59, 1178-1185.	0.8	23
164	Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2030-2037.	1.4	55
165	Rational Use of Antibiotics in the ICU. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1403.	3.8	26
166	Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. <i>Critical Care</i> , 2014, 18, 596.	2.5	247
167	Reducing the Burden of Acute Respiratory Distress Syndrome. <i>Shock</i> , 2014, 41, 378-387.	1.0	21
168	Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to <i>Pseudomonas aeruginosa</i> *. <i>Critical Care Medicine</i> , 2014, 42, 2178-2187.	0.4	157
169	Identifying Critically Ill Patients at Risk for Inappropriate Antibiotic Therapy. <i>Critical Care Medicine</i> , 2014, 42, 1832-1838.	0.4	21
170	Using the Number Needed to Treat to Assess Appropriate Antimicrobial Therapy as a Determinant of Outcome in Severe Sepsis and Septic Shock*. <i>Critical Care Medicine</i> , 2014, 42, 2342-2349.	0.4	88
171	Clinical implications for patients treated inappropriately for community-acquired pneumonia in the emergency department. <i>BMC Infectious Diseases</i> , 2014, 14, 61.	1.3	28
172	Conservative fluid therapy in septic shock: an example of targeted therapeutic minimization. <i>Critical Care</i> , 2014, 18, 481.	2.5	10
173	Probiotics for preventing ventilator-associated pneumonia. <i>The Cochrane Library</i> , 2014, , CD009066.	1.5	104
174	Effects of Empiric Antifungal Therapy for Septic Shock on Time to Appropriate Therapy for Candida Infection: A Pilot Study. <i>Clinical Therapeutics</i> , 2014, 36, 1226-1232.	1.1	10
175	What can be expected from antimicrobial de-escalation in the critically ill?. <i>Intensive Care Medicine</i> , 2014, 40, 92-95.	3.9	15
176	Candidemia and non-candidemia related septic shock: are there differences between them?. <i>Intensive Care Medicine</i> , 2014, 40, 1046-1048.	3.9	3
177	Ventilator-Associated Pneumonia Prevention. <i>Chest</i> , 2014, 146, 873-874.	0.4	3
178	Ventilator-associated Complications, Including Infection-related Complications. <i>Critical Care Clinics</i> , 2013, 29, 33-50.	1.0	22
179	A risk score for identifying methicillin-resistant <i>Staphylococcus aureus</i> in patients presenting to the hospital with pneumonia. <i>BMC Infectious Diseases</i> , 2013, 13, 268.	1.3	67
180	Determinants of Hospital Mortality Among Patients with Sepsis or Septic Shock Receiving Appropriate Antibiotic Treatment. <i>Current Infectious Disease Reports</i> , 2013, 15, 400-406.	1.3	11

#	ARTICLE	IF	CITATIONS
181	Prolonged Infusion Antibiotics for Suspected Gram-Negative Infections in the ICU: A Before-After Study. <i>Annals of Pharmacotherapy</i> , 2013, 47, 170-180.	0.9	44
182	Azithromycin and survival in <i>Streptococcus pneumoniae</i> pneumonia: a retrospective study. <i>BMJ Open</i> , 2013, 3, e002898.	0.8	12
183	Aerosolized antibiotics. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 538-544.	1.3	45
184	Developing a New, National Approach to Surveillance for Ventilator-Associated Events*. <i>Critical Care Medicine</i> , 2013, 41, 2467-2475.	0.4	634
185	Readmission Following Hospitalization for Pneumonia: The Impact of Pneumonia Type and Its Implication for Hospitals. <i>Clinical Infectious Diseases</i> , 2013, 57, 362-367.	2.9	48
186	Developing a New, National Approach to Surveillance for Ventilator-Associated Events: Executive Summary. <i>Clinical Infectious Diseases</i> , 2013, 57, 1742-1746.	2.9	55
187	Fluid balance and cardiac function in septic shock as predictors of hospital mortality. <i>Critical Care</i> , 2013, 17, R246.	2.5	123
188	Ventilator-Associated Tracheobronchitis and Ventilator-Associated Pneumonia. <i>Chest</i> , 2013, 144, 3-5.	0.4	3
189	Short- vs Long-Duration Antibiotic Regimens for Ventilator-Associated Pneumonia. <i>Chest</i> , 2013, 144, 1759-1767.	0.4	127
190	Probiotics for Ventilator-Associated Pneumonia. <i>Chest</i> , 2013, 143, 590-592.	0.4	4
191	Preventive Strategies in VAP: Focus on Silver-Coated Endotracheal Tubes. , 2013, , 531-555.		2
192	Patients Hospitalized With Pneumonia: Determining the Need for Broad-Spectrum Antibiotic Therapy. <i>Clinical Infectious Diseases</i> , 2012, 54, 479-482.	2.9	6
193	Use of Adjunctive Aerosolized Antimicrobial Therapy in the Treatment of <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> Ventilator-Associated Pneumonia. <i>Respiratory Care</i> , 2012, 57, 1226-1233.	0.8	84
194	Validation of a Clinical Score for Assessing the Risk of Resistant Pathogens in Patients With Pneumonia Presenting to the Emergency Department. <i>Clinical Infectious Diseases</i> , 2012, 54, 193-198.	2.9	148
195	Septic Shock Attributed to <i>Candida</i> Infection: Importance of Empiric Therapy and Source Control. <i>Clinical Infectious Diseases</i> , 2012, 54, 1739-1746.	2.9	377
196	A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria*. <i>Critical Care Medicine</i> , 2012, 40, 281-284.	0.4	115
197	The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment*. <i>Critical Care Medicine</i> , 2012, 40, 2016-2021.	0.4	68
198	Prevention of ventilator-associated pneumonia or ventilator-associated complications. <i>Critical Care Medicine</i> , 2012, 40, 271-277.	0.4	29

#	ARTICLE	IF	CITATIONS
199	Antimicrobial stewardship programs: mandatory for all ICUs. <i>Critical Care</i> , 2012, 16, 179.	2.5	37
200	A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. <i>Critical Care</i> , 2012, 16, R218.	2.5	173
201	Risk Factors for Mixed Complicated Skin and Skin Structure Infections To Help Tailor Appropriate Empiric Therapy. <i>Surgical Infections</i> , 2012, 13, 377-382.	0.7	11
202	Economic Impact of Ventilator-Associated Pneumonia in a Large Matched Cohort. <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 250-256.	1.0	303
203	Linezolid in Methicillin-Resistant <i>Staphylococcus aureus</i> Nosocomial Pneumonia: A Randomized, Controlled Study. <i>Clinical Infectious Diseases</i> , 2012, 54, 621-629.	2.9	513
204	An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. <i>BMC Infectious Diseases</i> , 2012, 12, 56.	1.3	33
205	Hospital-Acquired Pneumonia. , 2012, , 137-145.		1
206	Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens. <i>Clinical Infectious Diseases</i> , 2011, 52, 31-40.	2.9	239
207	Healthcare-Associated Pneumonia: Approach to Management. <i>Clinics in Chest Medicine</i> , 2011, 32, 507-515.	0.8	8
208	Medical Data Mining for Early Deterioration Warning in General Hospital Wards. , 2011, , .		25
209	Healthcare-associated pneumonia: Diagnostic criteria and distinction from community-acquired pneumonia. <i>International Journal of Infectious Diseases</i> , 2011, 15, e545-e550.	1.5	55
210	Implementation of a real-time computerized sepsis alert in nonintensive care unit patients*. <i>Critical Care Medicine</i> , 2011, 39, 469-473.	0.4	145
211	Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis*. <i>Critical Care Medicine</i> , 2011, 39, 1859-1865.	0.4	87
212	Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay*. <i>Critical Care Medicine</i> , 2011, 39, 46-51.	0.4	162
213	Health Care-Associated Pneumonia (HCAP). <i>Medicine (United States)</i> , 2011, 90, 390-395.	0.4	39
214	Hospital-acquired pneumonia/ventilator-associated pneumonia prevention: Truth or dare!*. <i>Critical Care Medicine</i> , 2011, 39, 2015-2016.	0.4	0
215	<i>Clostridium difficile</i> in the ICU. <i>Chest</i> , 2011, 140, 1643-1653.	0.4	62
216	Ventilator-Associated Tracheobronchitis in a Mixed Surgical and Medical ICU Population. <i>Chest</i> , 2011, 139, 513-518.	0.4	84

#	ARTICLE	IF	CITATIONS
217	Institutional Perspective on the Impact of Positive Blood Cultures on the Economic and Clinical Outcomes of Patients With Complicated Skin and Skin Structure Infections: Focus on Gram-Positive Infections. <i>Clinical Therapeutics</i> , 2011, 33, 1759-1768.e1.	1.1	2
218	Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: A multicenter cohort study. <i>Journal of Infection</i> , 2011, 62, 130-135.	1.7	90
219	Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with gram-negative bacteremia. <i>Journal of Hospital Medicine</i> , 2011, 6, 405-410.	0.7	55
220	Antibiotic Stewardship in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 215-227.	0.8	38
221	Diagnostic Utility of Plasma Procalcitonin for Nosocomial Pneumonia in the Intensive Care Unit Setting. <i>Respiratory Care</i> , 2011, 56, 412-419.	0.8	30
222	Appraising Contemporary Strategies to Combat Multidrug Resistant Gram-Negative Bacterial Infections—Proceedings and Data From the Gram-Negative Resistance Summit. <i>Clinical Infectious Diseases</i> , 2011, 53, S33-S55.	2.9	88
223	Prevention of Nosocomial Pneumonia in the Intensive Care Unit: Beyond the Use of Bundles. <i>Surgical Infections</i> , 2011, 12, 211-220.	0.7	22
224	Recognition of Nosocomial Pneumonia in the Intensive Care Unit: Still a Confusing Issue. <i>Respiratory Care</i> , 2011, 56, 1209-1212.	0.8	3
225	Early Deterioration Warning for Hospitalized Patients by Mining Clinical Data. <i>International Journal of Knowledge Discovery in Bioinformatics</i> , 2011, 2, 1-20.	0.8	6
226	Activity of a silver-coated endotracheal tube in preclinical models of ventilator-associated pneumonia and a study after extubation*. <i>Critical Care Medicine</i> , 2010, 38, 1135-1140.	0.4	58
227	Recognition and prevention of nosocomial pneumonia in the intensive care unit and infection control in mechanical ventilation. <i>Critical Care Medicine</i> , 2010, 38, S352-S362.	0.4	62
228	Methicillin-resistant <i>Staphylococcus aureus</i> nasal colonization is a poor predictor of intensive care unit-acquired methicillin-resistant <i>Staphylococcus aureus</i> infections requiring antibiotic treatment. <i>Critical Care Medicine</i> , 2010, 38, 1991-1995.	0.4	61
229	A Comparison of Culture-Positive and Culture-Negative Health-Care-Associated Pneumonia. <i>Chest</i> , 2010, 137, 1130-1137.	0.4	87
230	A magic bullet for sepsis: Getting back to the basics*. <i>Critical Care Medicine</i> , 2010, 38, 733-734.	0.4	0
231	The Resuscitation Package in Sepsis. <i>Current Infectious Disease Reports</i> , 2010, 12, 368-373.	1.3	1
232	Hospital Resource Utilization and Costs of Inappropriate Treatment of Candidemia. <i>Pharmacotherapy</i> , 2010, 30, 361-368.	1.2	82
233	Hospitalizations with healthcare-associated complicated skin and skin structure infections: Impact of inappropriate empiric therapy on outcomes. <i>Journal of Hospital Medicine</i> , 2010, 5, 535-540.	0.7	41
234	Probiotic Prophylaxis of Ventilator-associated Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1058-1064.	2.5	308

#	ARTICLE	IF	CITATIONS
235	Review of Recent Clinical Trials of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Perspective from Academia. <i>Clinical Infectious Diseases</i> , 2010, 51, S29-S35.	2.9	21
236	Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Nasal Colonization Predicts Intensive Care Unit-Acquired MRSA Infections: True Or False?. <i>Surgical Infections</i> , 2010, 11, 497-499.	0.7	7
237	Association Between a Silver-Coated Endotracheal Tube and Reduced Mortality in Patients With Ventilator-Associated Pneumonia. <i>Chest</i> , 2010, 137, 1015-1021.	0.4	61
238	Increased Mortality in Patients Without Ventilator-Associated Pneumonia: Response. <i>Chest</i> , 2010, 138, 1275.	0.4	3
239	Health Care-Associated Pneumonia. <i>Hospital Practice (1995)</i> , 2010, 38, 63-74.	0.5	4
240	Economic Burden of Ventilator-Associated Pneumonia Based on Total Resource Utilization. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 509-515.	1.0	100
241	<i>Staphylococcus aureus</i> Nasal Colonization and Subsequent Infection in Intensive Care Unit Patients: Does Methicillin Resistance Matter?. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 584-591.	1.0	90
242	Predicting Bacteremia among Patients Hospitalized for Skin and Skin-Structure Infections: Derivation and Validation of a Risk Score. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 828-837.	1.0	30
243	Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators. <i>Critical Care</i> , 2010, 14, R84.	2.5	10
244	Will procalcitonin reduce antibiotic use in intensive care?. <i>Lancet, The</i> , 2010, 375, 435-436.	6.3	9
245	Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1742-1748.	1.4	221
246	Bacteremia Increases the Risk of Death among Patients with Soft-Tissue Infections. <i>Surgical Infections</i> , 2010, 11, 169-176.	0.7	15
247	Health-Care-Associated Pneumonia. <i>Chest</i> , 2009, 135, 594-596.	0.4	4
248	The Importance of Fluid Management in Acute Lung Injury Secondary to Septic Shock. <i>Chest</i> , 2009, 136, 102-109.	0.4	436
249	Clinical Practice Improvement Initiatives. <i>Chest</i> , 2009, 136, 335-338.	0.4	5
250	The Flood and Ebb of Septic Shock: Response. <i>Chest</i> , 2009, 136, 1705-1706.	0.4	0
251	The Alphabet Soup of Pneumonia: CAP, HAP, HCAP, NHAP, and VAP. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 003-009.	0.8	60
252	Severe hospital-acquired pneumonia: A review for clinicians. <i>Current Infectious Disease Reports</i> , 2009, 11, 349-356.	1.3	7

#	ARTICLE	IF	CITATIONS
253	Candidemia on presentation to the hospital: development and validation of a risk score. <i>Critical Care</i> , 2009, 13, R156.	2.5	36
254	Diagnostic Implications of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in BAL Fluid of Patients With Pulmonary Infiltrates in the ICU. <i>Chest</i> , 2009, 135, 641-647.	0.4	73
255	Preface. <i>Infectious Disease Clinics of North America</i> , 2009, 23, xiii-xiv.	1.9	1
256	Cost-Effectiveness Analysis of a Silver-Coated Endotracheal Tube to Reduce the Incidence of Ventilator-Associated Pneumonia. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 759-763.	1.0	67
257	Epidemiology and Outcomes of Hospitalizations with Complicated Skin and Skin-Structure Infections: Implications of Healthcare-Associated Infection Risk Factors. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 1203-1210.	1.0	49
258	Implementing quality improvements in the intensive care unit: Ventilator bundle as an example. <i>Critical Care Medicine</i> , 2009, 37, 305-309.	0.4	85
259	Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis*. <i>Critical Care Medicine</i> , 2009, 37, 819-824.	0.4	105
260	Oral Decontamination to Prevent Ventilator-Associated Pneumonia. <i>Chest</i> , 2009, 135, 1116-1118.	0.4	10
261	VAT vs VAP. <i>Chest</i> , 2009, 135, 252-255.	0.4	11
262	Epidemiology and Outcomes of Clostridium difficile -Associated Disease Among Patients on Prolonged Acute Mechanical Ventilation. <i>Chest</i> , 2009, 136, 752-758.	0.4	45
263	Soluble Triggering Receptor Expressed on Myeloid Cells 1 and the Diagnosis of Ventilator-Associated Pneumonia: Response. <i>Chest</i> , 2009, 136, 320.	0.4	3
264	New antimicrobial agents for methicillin-resistant Staphylococcus aureus. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2009, 11, 282-6.	0.0	10
265	Health care-associated pneumonia: identification and initial management in the ED. <i>American Journal of Emergency Medicine</i> , 2008, 26, 1-11.	0.7	112
266	Secular Trends in Candidemia-Related Hospitalization in the United States, 2000-2005. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 978-980.	1.0	123
267	Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 805.	3.8	414
268	Introduction: Update on the Appropriate Use of Meropenem for the Treatment of Serious Bacterial Infections. <i>Clinical Infectious Diseases</i> , 2008, 47, S1-S2.	2.9	10
269	Antimicrobial Therapy Escalation and Hospital Mortality Among Patients With Health-Care-Associated Pneumonia. <i>Chest</i> , 2008, 134, 963-968.	0.4	134
270	Health Care-Associated Pneumonia (HCAP): A Critical Appraisal to Improve Identification, Management, and Outcomes-Proceedings of the HCAP Summit. <i>Clinical Infectious Diseases</i> , 2008, 46, S296-S334.	2.9	111

#	ARTICLE	IF	CITATIONS
271	Pneumonia Caused by Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Clinical Infectious Diseases</i> , 2008, 46, S378-S385.	2.9	291
272	Broad-Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front. <i>Clinical Infectious Diseases</i> , 2008, 47, S3-S13.	2.9	213
273	Prediction of Infection Due to Antibiotic-Resistant Bacteria by Select Risk Factors for Health Care-Associated Pneumonia. <i>Archives of Internal Medicine</i> , 2008, 168, 2205.	4.3	194
274	Health Care-Associated Infection (HAI): A Critical Appraisal of the Emerging Threat—Proceedings of the HAI Summit. <i>Clinical Infectious Diseases</i> , 2008, 47, S55-S99.	2.9	56
275	SMART Approaches for Reducing Nosocomial Infections in the ICU. <i>Chest</i> , 2008, 134, 447-456.	0.4	39
276	Predictors of 30-Day Mortality and Hospital Costs in Patients With Ventilator-Associated Pneumonia Attributed to Potentially Antibiotic-Resistant Gram-Negative Bacteria. <i>Chest</i> , 2008, 134, 281-287.	0.4	238
277	A 50-Year-Old Woman With Abdominal Pain and Respiratory Failure 3 Months After Kidney Transplantation. <i>Chest</i> , 2008, 134, 442-446.	0.4	16
278	The Modified APACHE II Score Outperforms CURB65 Pneumonia Severity Score as a Predictor of 30-Day Mortality in Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Pneumonia. <i>Chest</i> , 2008, 133, 363-369.	0.4	38
279	The Importance of Early Treatment With Doxycycline in Human Ehrlichiosis. <i>Medicine (United States)</i> , 2008, 87, 53-60.	0.4	54
280	Inappropriate therapy for methicillin-resistant <i>Staphylococcus aureus</i> : Resource utilization and cost implications*. <i>Critical Care Medicine</i> , 2008, 36, 2335-2340.	0.4	72
281	Treatment-related risk factors for hospital mortality in <i>Candida</i> bloodstream infections*. <i>Critical Care Medicine</i> , 2008, 36, 2967-2972.	0.4	158
282	Health Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center Experience. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3568-3573.	1.4	367
283	Bugging the Bugs: Novel Approaches in the Strategic Management of Resistant <i>Staphylococcus aureus</i> Infections. <i>Clinical Infectious Diseases</i> , 2007, 45, S163-S164.	2.9	2
284	Optimizing Therapy for MRSA Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 615-623.	0.8	7
285	Addition of Vasopressin to Norepinephrine as Independent Predictor of Mortality in Patients with Refractory Septic Shock: An Observational Study. <i>Surgical Infections</i> , 2007, 8, 189-200.	0.7	20
286	Moving Towards Real-Time Antimicrobial Management of Ventilator-Associated Pneumonia. <i>Clinical Infectious Diseases</i> , 2007, 44, 388-390.	2.9	19
287	Limitations of Vancomycin in the Management of Resistant Staphylococcal Infections. <i>Clinical Infectious Diseases</i> , 2007, 45, S191-S195.	2.9	153
288	Probiotics for Preventing and Treating Nosocomial Infections. <i>Chest</i> , 2007, 132, 286-294.	0.4	53

#	ARTICLE	IF	CITATIONS
289	Correctly scoring infections: CSI in the ICU*. Critical Care Medicine, 2007, 35, 2641-2643.	0.4	0
290	Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Critical Care Medicine, 2007, 35, 1077-1083.	0.4	118
291	Economic implications of an evidence-based sepsis protocol: Can we improve outcomes and lower costs?*. Critical Care Medicine, 2007, 35, 1257-1262.	0.4	724
292	A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clinical Therapeutics, 2007, 29, 1107-1115.	1.1	303
293	Use of Hypochlorite Solution to Decrease Rates of Clostridium difficile-Associated Diarrhea. Infection Control and Hospital Epidemiology, 2007, 28, 205-207.	1.0	64
294	The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections. Drugs, 2007, 67, 351-368.	4.9	710
295	Predictors of In-Hospital Mortality for Bloodstream Infections Caused by Enterobacter Species or Citrobacter freundii. Pharmacotherapy, 2007, 27, 191-199.	1.2	37
296	Early Appropriate Empiric Therapy and Antimicrobial De-Escalation. Infectious Disease and Therapy, 2007, , 231-250.	0.0	0
297	The Intensive Care Unit as a Research Laboratory: Developing Strategies to Prevent Antimicrobial Resistance. Surgical Infections, 2006, 7, 85-99.	0.7	5
298	Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Critical Care, 2006, 10, R97.	2.5	120
299	Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen?. Current Opinion in Infectious Diseases, 2006, 19, 161-168.	1.3	63
300	Clinical Characteristics and Treatment Patterns Among Patients With Ventilator-Associated Pneumonia. Chest, 2006, 129, 1210-1218.	0.4	352
301	Time To Get Serious About Infection Prevention in the ICU. Chest, 2006, 130, 1293-1296.	0.4	14
302	Beforeâ€“after study of a standardized hospital order set for the management of septic shock*. Critical Care Medicine, 2006, 34, 2707-2713.	0.4	424
303	Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment*. Critical Care Medicine, 2006, 34, 2069-2074.	0.4	136
304	Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study*. Critical Care Medicine, 2006, 34, 2766-2772.	0.4	144
305	Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Critical Care Medicine, 2006, 34, 700-706.	0.4	130
306	Providing appropriate antimicrobial therapy in the intensive care unit: Surveillance vs. de-escalation*. Critical Care Medicine, 2006, 34, 903-905.	0.4	33

#	ARTICLE	IF	CITATIONS
307	Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database*. Critical Care Medicine, 2006, 34, 2588-2595.	0.4	270
308	Predictors of Mortality for Methicillin-Resistant Staphylococcus aureus Health-Care-Associated Pneumonia. Chest, 2006, 130, 947-955.	0.4	237
309	Optimizing Antibiotic Treatment for Ventilator-Associated Pneumonia. Pharmacotherapy, 2006, 26, 204-213.	1.2	27
310	Microbiological Diagnosis of Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1182-1184.	2.5	13
311	Diagnosis of Ventilator-Associated Pneumonia. New England Journal of Medicine, 2006, 355, 2691-2693.	13.9	60
312	Is Antibiotic Cycling the Answer to Preventing the Emergence of Bacterial Resistance in the Intensive Care Unit?. Clinical Infectious Diseases, 2006, 43, S82-S88.	2.9	78
313	A Randomized Double-Blind Trial of Iseganan in Prevention of Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 91-97.	2.5	110
314	Prevention of nosocomial respiratory infections. , 2006, , 675-693.		0
315	Strategies to prevent antimicrobial resistance in the intensive care unit. Critical Care Medicine, 2005, 33, 1845-1853.	0.4	129
316	Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis. Critical Care Medicine, 2005, 33, 46-53.	0.4	214
317	Pleuropulmonary Complications of Panton-Valentine Leukocidin-Positive Community-Acquired Methicillin-Resistant Staphylococcus aureus. Chest, 2005, 128, 2732-2738.	0.4	181
318	Antibiotic Utilization and Outcomes for Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative BAL Culture Results. Chest, 2005, 128, 2706-2713.	0.4	108
319	Prevention of hospital infection. Microbes and Infection, 2005, 7, 268-274.	1.0	10
320	The importance of antimicrobial resistance in hospital-acquired and ventilator-associated pneumonia. Current Anaesthesia and Critical Care, 2005, 16, 209-219.	0.3	2
321	Predictors of Hospital Mortality for Patients with Severe Sepsis Treated with Drotrecogin alfa (activated). Pharmacotherapy, 2005, 25, 26-34.	1.2	39
322	Pseudomonas aeruginosa Bloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment. Antimicrobial Agents and Chemotherapy, 2005, 49, 1306-1311.	1.4	485
323	Quinolones for Treatment of Nosocomial Pneumonia: A Meta-Analysis. Clinical Infectious Diseases, 2005, 40, S115-S122.	2.9	24
324	Epidemiology and Outcomes of Health-care-Associated Pneumonia. Chest, 2005, 128, 3854-3862.	0.4	931

#	ARTICLE	IF	CITATIONS
325	Transfusion Practice and Blood Stream Infections in Critically Ill Patients. <i>Chest</i> , 2005, 127, 1722-1728.	0.4	115
326	Prevention of Pneumonia in the Hospital Setting. <i>Clinics in Chest Medicine</i> , 2005, 26, 135-142.	0.8	4
327	Gram-Negative Bacterial Resistance: Evolving Patterns and Treatment Paradigms. <i>Clinical Infectious Diseases</i> , 2005, 40, S85-S88.	2.9	33
328	Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3640-3645.	1.4	1,191
329	Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit. <i>Critical Care</i> , 2005, 9, 459.	2.5	23
330	What is ventilator-associated pneumonia and why is it important?. <i>Respiratory Care</i> , 2005, 50, 714-21; discussion 721-4.	0.8	82
331	Risk Factors for Ventilator-Associated Pneumonia: From Epidemiology to Patient Management. <i>Clinical Infectious Diseases</i> , 2004, 38, 1141-1149.	2.9	258
332	Hospital Mortality for Patients With Bacteremia Due to Staphylococcus aureus or Pseudomonas aeruginosa. <i>Chest</i> , 2004, 125, 607-616.	0.4	153
333	Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. <i>Intensive Care Medicine</i> , 2004, 30, 388-394.	3.9	301
334	A Cost-Benefit Analysis of Gown Use in Controlling Vancomycin-Resistant Enterococcus Transmission Is It Worth the Price?. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 418-424.	1.0	68
335	Red blood cell transfusion and ventilator-associated pneumonia: A potential link?. <i>Critical Care Medicine</i> , 2004, 32, 666-674.	0.4	202
336	Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. <i>Critical Care Medicine</i> , 2004, 32, 1396-1405.	0.4	373
337	Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. <i>Critical Care Medicine</i> , 2004, 32, 2450-2456.	0.4	104
338	A Randomized Controlled Trial of an Antibiotic Discontinuation Policy for Clinically Suspected Ventilator-Associated Pneumonia. <i>Chest</i> , 2004, 125, 1791-1799.	0.4	349
339	The Effect of an Education Program on the Incidence of Central Venous Catheter-Associated Bloodstream Infection in a Medical ICU. <i>Chest</i> , 2004, 126, 1612-1618.	0.4	235
340	An Educational Intervention to Reduce Ventilator-Associated Pneumonia in an Integrated Health System. <i>Chest</i> , 2004, 125, 2224-2231.	0.4	207
341	Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. <i>Respiratory Care</i> , 2004, 49, 1530-41.	0.8	27
342	Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. <i>Intensive Care Medicine</i> , 2003, 29, 147-149.	3.9	29

#	ARTICLE	IF	CITATIONS
343	Management of Severe Sepsis: Integration of Multiple Pharmacologic Interventions. <i>Pharmacotherapy</i> , 2003, 23, 1486-1496.	1.2	16
344	Ventilator-Associated Pneumonia in a Multi-Hospital System Differences in Microbiology by Location. <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 853-858.	1.0	67
345	Appropriate Empirical Antibacterial Therapy for Nosocomial Infections. <i>Drugs</i> , 2003, 63, 2157-2168.	4.9	123
346	Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. <i>Clinical Therapeutics</i> , 2003, 25, 980-992.	1.1	227
347	Linezolid vs Vancomycin *. <i>Chest</i> , 2003, 124, 1789-1797.	0.4	590
348	Nursing adherence with evidence-based guidelines for preventing ventilator-associated pneumonia*. <i>Critical Care Medicine</i> , 2003, 31, 2693-2696.	0.4	152
349	Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center*. <i>Critical Care Medicine</i> , 2003, 31, 1312-1317.	0.4	511
350	Selective Digestive Decontamination Should Not Be Routinely Employed*. <i>Chest</i> , 2003, 123, 464S-468S.	0.4	101
351	Improving Family Communications at the End of Life: Implications for Length of Stay in the Intensive Care Unit and Resource Use. <i>American Journal of Critical Care</i> , 2003, 12, 317-324.	0.8	150
352	Why Do Physicians Not Follow Evidence-Based Guidelines for Preventing Ventilator-Associated Pneumonia?. <i>Chest</i> , 2002, 122, 656-661.	0.4	221
353	Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database. <i>Chest</i> , 2002, 122, 2115-2121.	0.4	1,089
354	Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia*. <i>Critical Care Medicine</i> , 2002, 30, 2407-2412.	0.4	288
355	Clinical Importance of Delays in the Initiation of Appropriate Antibiotic Treatment for Ventilator-Associated Pneumonia. <i>Chest</i> , 2002, 122, 262-268.	0.4	912
356	Silver-Coated Endotracheal Tubes Associated With Reduced Bacterial Burden in the Lungs of Mechanically Ventilated Dogs. <i>Chest</i> , 2002, 121, 863-870.	0.4	173
357	Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. <i>Journal of Parenteral and Enteral Nutrition</i> , 2002, 26, 174-181.	1.3	280
358	Prevention of Antibiotic Resistance in Hospitals. <i>Annals of Internal Medicine</i> , 2002, 136, 173.	2.0	0
359	Antibiotic Resistance in the Intensive Care Unit. <i>Annals of Internal Medicine</i> , 2001, 134, 298.	2.0	382
360	Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. <i>Critical Care Medicine</i> , 2001, 29, 1109-1115.	0.4	536

#	ARTICLE	IF	CITATIONS
361	Mechanical Ventilator Weaning Protocols Driven by Nonphysician Health-Care Professionals. <i>Chest</i> , 2001, 120, 454S-463S.	0.4	240
362	The Occurrence of Ventilator-Associated Pneumonia in a Community Hospital. <i>Chest</i> , 2001, 120, 555-561.	0.4	310
363	A Comparative Analysis of Patients With Early-Onset vs Late-Onset Nosocomial Pneumonia in the ICU Setting. <i>Chest</i> , 2000, 117, 1434-1442.	0.4	256
364	Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. <i>Critical Care Medicine</i> , 2000, 28, 3456-3464.	0.4	153
365	Inadequate Antimicrobial Treatment: An Important Determinant of Outcome for Hospitalized Patients. <i>Clinical Infectious Diseases</i> , 2000, 31, S131-S138.	2.9	553
366	The Influence of Inadequate Antimicrobial Treatment of Bloodstream Infections on Patient Outcomes in the ICU Setting. <i>Chest</i> , 2000, 118, 146-155.	0.4	1,641
367	Inadequate Antimicrobial Treatment of Infections. <i>Chest</i> , 1999, 115, 462-474.	0.4	1,740
368	The Prevention of Ventilator-Associated Pneumonia. <i>New England Journal of Medicine</i> , 1999, 340, 627-634.	13.9	504
369	A Randomized Clinical Trial of Continuous Aspiration of Subglottic Secretions in Cardiac Surgery Patients. <i>Chest</i> , 1999, 116, 1339-1346.	0.4	314
370	Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. <i>Critical Care Medicine</i> , 1999, 27, 2609-2615.	0.4	1,040
371	The Influence of Mini-BAL Cultures on Patient Outcomes. <i>Chest</i> , 1998, 113, 412-420.	0.4	525
372	A Randomized Clinical Trial Comparing an Extended-Use Hygroscopic Condenser Humidifier With Heated-Water Humidification in Mechanically Ventilated Patients. <i>Chest</i> , 1998, 113, 759-767.	0.4	384
373	High levels of C-reactive protein and positive troponin T test results predicted 14-day mortality in unstable angina or non-Q-wave MI. <i>ACP Journal Club</i> , 1998, 129, 73.	0.1	0
374	A randomized, controlled trial of protocol-directed versus physician-directed weaning from mechanical ventilation. <i>Critical Care Medicine</i> , 1997, 25, 567-574.	0.4	743
375	The Safety and Diagnostic Accuracy of Minibronchoalveolar Lavage in Patients with Suspected Ventilator-Associated Pneumonia. <i>Annals of Internal Medicine</i> , 1995, 122, 743.	2.0	194
376	The Effect of Late-Onset Ventilator-Associated Pneumonia in Determining Patient Mortality. <i>Chest</i> , 1995, 108, 1655-1662.	0.4	376
377	Mechanical Ventilation with or without 7-Day Circuit Changes. <i>Annals of Internal Medicine</i> , 1995, 123, 168.	2.0	151
378	Ventilator-Associated Pneumonia. <i>JAMA - Journal of the American Medical Association</i> , 1993, 270, 1965.	3.8	536

#	ARTICLE	IF	CITATIONS
379	A Persistent Left Lower Lobe Infiltrate and Chronic Cough Following Chest Wounds Sustained in Vietnam Twenty-Four Years Earlier. <i>Military Medicine</i> , 1993, 158, 499-500.	0.4	0
380	Staphylococcal Pneumonia. , 0, , 444-454.		0